Related Experiment Video
Updated: Dec 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a
Takashi Kawahara1,2, Sahoko Ninomiya1, Yasuhide Miyoshi1
1Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.
Introduction:
In June 2018, enzalutamide began to be sold in a tablet form in Japan and Germany. We herein report the case of an improvement in prostate cancer progression due to changing enzalutamide dosage form from a capsule to a tablet.
Case Presentation:
A 76-year-old man was initially referred to our hospital for the further examination of his elevated prostate-specific antigen level (3664.0 ng/mL). He had developed castration-resistant prostate cancer 10 months after initial treatment. Treatment with enzalutamide (capsule form) was subsequently initiated. In June 2018, drug form of enzalutamide was changed from a capsule to a tablet. After switching to an enzalutamide tablet, his prostate-specific antigen level decreased significantly from 493.0 to 26.5 ng/mL.
Conclusion:
While the reason for this prostate-specific antigen response is unclear, changing the enzalutamide form from a capsule to a tablet may have improved the adherence of drug intake and thereby resulted in castration-resistant prostate cancer control.
More Related Videos
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
Related Concept Videos
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioavailability Enhancement: Drug Permeability Enhancement
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems